Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abuse Potential of Buprenorphine/Naloxone in Opioid Dependent Individuals
NCT00149539Phase 2Terminated
- Sponsor
- National Institute on Drug Abuse
- Start
- Jun 2004
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2 trial of buprenorphine and naloxone in opioid use disorder (OUD) (2 arms), sponsored by National Institute on Drug Abuse. Primary endpoints: Opiate withdrawal up to 1 day, Opiate agonist symptoms up to 1 day and 1 more. Started Jun 2004; status: terminated.
02
Drugs
buprenorphinenaloxone
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT00149539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00149539.